ATE197158T1 - Verbindungen mit wachstumshormonfreisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormonfreisetzenden eigenschaften

Info

Publication number
ATE197158T1
ATE197158T1 AT95903774T AT95903774T ATE197158T1 AT E197158 T1 ATE197158 T1 AT E197158T1 AT 95903774 T AT95903774 T AT 95903774T AT 95903774 T AT95903774 T AT 95903774T AT E197158 T1 ATE197158 T1 AT E197158T1
Authority
AT
Austria
Prior art keywords
growth hormone
compounds
hormone releasing
releasing properties
pct
Prior art date
Application number
AT95903774T
Other languages
English (en)
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Gersen Henning Th
Birgit Sehested Hansen
Bernd Peschke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE197158T1 publication Critical patent/ATE197158T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95903774T 1993-12-23 1994-12-22 Verbindungen mit wachstumshormonfreisetzenden eigenschaften ATE197158T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (de) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14
PCT/DK1994/000485 WO1995017423A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ATE197158T1 true ATE197158T1 (de) 2000-11-15

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903774T ATE197158T1 (de) 1993-12-23 1994-12-22 Verbindungen mit wachstumshormonfreisetzenden eigenschaften

Country Status (27)

Country Link
US (1) US5767085A (de)
EP (1) EP0736039B1 (de)
JP (1) JP3181918B2 (de)
KR (1) KR100354897B1 (de)
CN (1) CN1052731C (de)
AT (1) ATE197158T1 (de)
AU (1) AU689181B2 (de)
BR (1) BR9408377A (de)
CA (1) CA2179597A1 (de)
CZ (1) CZ293113B6 (de)
DE (1) DE69426206T2 (de)
DK (1) DK0736039T3 (de)
ES (1) ES2153469T3 (de)
FI (1) FI962584A0 (de)
GR (1) GR3035150T3 (de)
HU (1) HU224345B1 (de)
IL (1) IL112112A (de)
MX (1) MX9500072A (de)
NO (1) NO315561B1 (de)
NZ (1) NZ277486A (de)
PL (1) PL181280B1 (de)
PT (1) PT736039E (de)
RO (1) RO115635B1 (de)
SG (1) SG55069A1 (de)
SK (1) SK281963B6 (de)
UA (1) UA42747C2 (de)
WO (1) WO1995017423A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5854211A (en) * 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
MY113488A (en) * 1995-01-27 2002-03-30 Novo Nordisk As Compounds with growth hormone releasing properties
HUP9802821A3 (en) * 1995-06-22 2000-03-28 Novo Nordisk As Compounds with growth hormone releasing properties
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
AU715856B2 (en) * 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1997040023A1 (en) * 1996-04-24 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP1184370B1 (de) * 1996-07-22 2005-09-14 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
AU3938797A (en) * 1996-08-29 1998-03-19 Novo Nordisk A/S Transdermal delivery of peptides
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
IL137007A0 (en) 1998-01-16 2001-06-14 Novo Nordisk As Compounds with growth hormone releasing properties
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
JP2002522058A (ja) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド イヌ成長ホルモン分泌促進物質受容体
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
EP1200111A1 (de) * 1999-06-04 2002-05-02 Novo Nordisk A/S Verbindungen zur behandlung katobolischer zustand bei andauender schwerer erkrankung
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
JP2007513065A (ja) * 2003-05-19 2007-05-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 粒径が制御された酸化チタンを含むハードゼラチンカプセルおよびそれを製造する方法
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
US20050261201A1 (en) * 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2021015A2 (de) * 2006-04-28 2009-02-11 The Administrators Of The Tulane Educational Fund Ghrelin/ghrp/ghsr-antagonisten und ihre verwendung
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
EP2155769B1 (de) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Schutz gegen gewebedegeneration
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP3023426A1 (de) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazonhemmerverbindungen und krebsbehandlungsverfahren
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
SG176717A1 (en) 2009-06-12 2012-01-30 Helsinn Therapeutics Us Inc Ipamorelin diacetate injection and infusion solutions
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US12012467B2 (en) 2017-03-28 2024-06-18 Regents Of The University Of Michigan Small molecule DCN1 inhibitors and therapeutic methods using the same
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
CN119930744B (zh) * 2025-01-20 2025-12-19 昆明理工大学 一种发酵马乳源小分子肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
WO1983002272A1 (en) * 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
JPH08502250A (ja) * 1992-09-25 1996-03-12 スミスクライン・ビーチャム・コーポレイション 成長ホルモン放出ペプチド
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)

Also Published As

Publication number Publication date
JPH09507217A (ja) 1997-07-22
US5767085A (en) 1998-06-16
CN1052731C (zh) 2000-05-24
DE69426206T2 (de) 2001-05-17
DK0736039T3 (da) 2001-02-12
MX9500072A (es) 1997-05-31
NO962665D0 (no) 1996-06-21
SK281963B6 (sk) 2001-09-11
WO1995017423A1 (en) 1995-06-29
SG55069A1 (en) 1998-12-21
DE69426206D1 (de) 2000-11-30
EP0736039A1 (de) 1996-10-09
PL181280B1 (pl) 2001-07-31
IL112112A (en) 2000-06-29
EP0736039B1 (de) 2000-10-25
UA42747C2 (uk) 2001-11-15
HUT73497A (en) 1996-08-28
RO115635B1 (ro) 2000-04-28
PT736039E (pt) 2001-04-30
NO962665L (no) 1996-08-23
NO315561B1 (no) 2003-09-22
JP3181918B2 (ja) 2001-07-03
FI962584L (fi) 1996-06-20
ES2153469T3 (es) 2001-03-01
NZ277486A (en) 1997-03-24
HU224345B1 (hu) 2005-08-29
FI962584A7 (fi) 1996-06-20
CZ183496A3 (en) 1997-02-12
HU9501947D0 (en) 1995-11-28
GR3035150T3 (en) 2001-04-30
PL315113A1 (en) 1996-10-14
AU689181B2 (en) 1998-03-26
SK82096A3 (en) 1997-01-08
BR9408377A (pt) 1997-08-19
FI962584A0 (fi) 1996-06-20
CA2179597A1 (en) 1995-06-29
CZ293113B6 (cs) 2004-02-18
AU1272495A (en) 1995-07-10
CN1138335A (zh) 1996-12-18
KR100354897B1 (ko) 2003-01-06
IL112112A0 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
DE69426206D1 (de) Verbindungen mit wachstumshormonfreisetzenden eigenschaften
MY113488A (en) Compounds with growth hormone releasing properties
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
MX9709278A (es) Dipeptidos que promueven la liberacion de la hormona de crecimiento, composiciones que los contienen y uso de los mismos.
ATE202785T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ES2121193T3 (es) Derivados de bencimidazoles.
ITRM910952A1 (it) Composizioni farmaceutiche contenenti gonadotropine.
ATE178072T1 (de) Neuartige polypeptide und ihre verwendung
ES2139081T3 (es) Composiciones farmaceuticas que contienen la hormona humana del crecimiento.
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
ATE114157T1 (de) Peptidverbindungen mit wachstumshormonfreisetzender aktivität.
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
BR0014145A (pt) Compostos de benzimidazol substituìdo por alcóxi, preparações farmacêuticas contendo o mesmo, e métodos de uso do mesmo
HU9202026D0 (en) Method and medical preparative for treatment of thrombocytopenie
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
AU6722498A (en) Disubstituted biphenyloxazolines
PL309339A1 (en) Novel triazoquinazolines, methods of obtaining them and their application
NO950114L (no) Amylin-antagonister og agonister
NO960048D0 (no) Difluorstaton-analoger
NZ510253A (en) Neuroprotection

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee